Feasibility of AI-powered assessment scoring: Can large language models replace human raters? حسب Michael Jaworski III (22156096)

"…<p><b>Objective:</b> To assess the feasibility, accuracy, and reliability of using ChatGPT-4.5 (early-access), a large language model (LLM), for automated scoring of Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) protocols. …"

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. حسب Jacqueline A. Jansen (14894276)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis حسب Dijkhorst P.J. (20584910)

Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. حسب David Henderson (4612354)

الموضوعات:

Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. حسب David Henderson (4612354)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 ^a indicates ≥1.50 SD (18.0) from the mean (33.1... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... حسب Luke R. Cavanah (19022435)

الموضوعات: